 | | Content |
|  | | Diabetes ~ equivalent to MI |
|
 | | Dia 3 |
|  | | Blood pressure and vascular risk in diabetes Best evidence: 2000 |
|
 | | Blood pressure: best evidence 2009 |
|  | | All-cause mortality |
|
 | | Dia 7 |
|  | | Population in ACCORD |
|
 | | Intensive BP lowering (<120) versus standard BP treatment (<140) |
|  | | Intensive BP lowering (<120) is not better than standard BP (<140) |
|
 | | Intensive BP lowering (<120) is not better than standard BP (<140) |
|  | | Aspirin in diabetes |
|
 | | Belch J et al. BMJ 2008; 337:1030-44. |
|  | | Role of glucose in CV-disease |
|
 | | Dia 15 |
|  | | Glucose control in ACCORD |
|
 | | Effect of intensive glucose regulation on major cardiovascular events |
|  | | UK General Practice Research Base 1986 –2008 Twee cohorten: intensivering van orale medicatie Intensivering naar insuline Sterfte versus HbA1c decilen |
|
 | | Survival versus HbA1c (oral treatment) |
|  | | Survival versus HbA1c (insulin treatment) |
|
 | | Atherosclerosis Risk in Communities (ARIC) study Populatie-based sample 11,092 persons No history of diabetes or cardiovascular disease HbA1c measured in whole blood samples 1990-1992 |
|  | | Higher HbA1c more CV-disease |
|
 | | Higher HbA1c more stroke |
|  | | Holman R ea. N Engl J Med 2008;359:1577-89. |
|
 | | Holman R ea. N Engl J Med 2008;359:1577-89. |
|  | | Interpretation |
|
 | | Dia 27 |
|  | | galega officinalis |
|
 | | Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy |
|  | | Metformin: evidence and pitfalls |
|
 | | SU-derivatives |
|  | | Pioglitazone versus gliclazide added to metformin |
|
 | | Time to treatment failure |
|  | | Thiazolidine-diones |
|
 | | Dia 35 |
|  | | Fracture risk in ADOPT |
|
 | | Thiazolidine-diones |
|  | | Alpha-glucosidase inhibitors |
|
 | | Diabetes Market Forecast to 2013 |
|  | | The incretin concept |
|
 | | Nauck MA ea. JCEM 1986; 63:492 |
|  | | Nauck MA ea. JCEM 1986; 63:492 |
|
 | | Incretin effect |
|  | | The incretin effect |
|
 | | “The incretins” |
|  | | Incretins (GLP-1 and GIP) Regulate Glucose Homeostasis Through Effects on Islet Cell Function |
|
 | | After release incretins are rapidly inactivated |
|  | | GLP-1 is Rapidly Degraded by the DPP-4 enzyme |
|
 | | Degradation of incretins can be decreased by inhibition of the DPP-4 enzyme |
|  | | Effect of sitagliptin on top of metformin |
|
 | | Vildagliptin Add-on to Metformin |
|  | | Dia 52 |
|
 | | DPP-4 remmers |
|  | | When to use incretins? |
|
 | | Dia 55 |
|  | | Effects of GLP-1 |
|
 | | General Prescribing Considerations: How It Is Supplied |
|  | | Effect of Exenatide on HbA1c (30 Weeks) |
|
 | | Effect of Exenatide on Body Weight |
|  | | Adverse Events |
|
 | | Insulin compared to GLP-1 analogue Change in HbA1c compared to baseline |
|  | | Insulin compared to GLP-1 analogue Effect on weight |
|
 | | Samenvatting GLP-1 analogen |
|  | | Approach after combination therapy |
|
 | | Dia 65 |
|  | | Shah ND, et al. NEJM 2010; 363:2081-4. |
|
 | | DeSouza C ea. Nat Rev Drug Discov 2009; 8:361-7. |
|  | | FDA guidance on CV outcome trials |
|
 | | MACE analysis: Major Adverse Cardiovascular Events |
|  | | Best JH et al. Diabetes Care 2010; on line |
|
 | | CV outcome trials investigating incretin based therapies |
|  | | Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy |
|
Deel deze pagina met collega's en vrienden: